Ipamorelin

What is Ipamorelin?

Ipamorelin is a pentapeptide growth hormone secretagogue — a synthetic compound that stimulates the pituitary gland to release growth hormone (GH) via the ghrelin receptor (GHSR-1a). Developed in the 1990s, it represented a significant advance in GH peptide research because of its exceptional selectivity: Ipamorelin stimulates GH release without meaningfully affecting cortisol, ACTH, or prolactin levels that characterized earlier, less-selective secretagogues.

This selectivity profile has made Ipamorelin the gold standard first-generation GHSR agonist for research requiring clean GH stimulation without confounding neuroendocrine effects.

Mechanism of Action

GHSR-1a Agonism

Ipamorelin binds and activates the growth hormone secretagogue receptor (GHSR-1a) on pituitary somatotrophs, triggering intracellular signaling cascades that stimulate GH synthesis and release. This is an entirely independent pathway from the hypothalamic GHRH signal — making Ipamorelin ideal for combination with GHRH analogues like CJC-1295 or Sermorelin.

Pulsatile GH Release

Unlike exogenous growth hormone administration, which produces continuous supraphysiological GH levels, Ipamorelin stimulates a discrete, pulsatile GH release that closely mimics the body's natural GH secretory pattern. This pulsatile pattern is important for maintaining receptor sensitivity and producing downstream effects (IGF-1 elevation, lipolysis, protein synthesis) without the receptor desensitization associated with continuous GH exposure.

Somatostatin Suppression

Ipamorelin partially suppresses somatostatin — the hypothalamic hormone that inhibits GH release. This dual action (increased stimulation + reduced inhibition) amplifies the net GH output, particularly when combined with a GHRH analogue that is simultaneously stimulating GH production through a separate pathway.

Key Research Findings

Growth Hormone Elevation

In animal studies, Ipamorelin produced significant, dose-dependent GH elevations with a peak occurring approximately 15-30 minutes post-administration and returning to baseline within 3 hours — a clean, defined pulse. IGF-1 levels show corresponding elevation in chronic dosing studies.

Body Composition

Chronic Ipamorelin administration in animal models demonstrated increased lean body mass, reduced fat mass, and improved bone mineral density — consistent with GH/IGF-1 axis activation. Skin thickness and collagen density also improved in aged rodent models.

Selectivity Advantage

The critical differentiator from GHRP-2 and GHRP-6: Ipamorelin produces equivalent GH stimulation with dramatically less cortisol and prolactin elevation. This makes it suitable for longer research protocols where chronic stress hormone elevation would confound results or cause adverse biological effects.

Sleep Quality

GH secretagogues preferentially enhance the slow-wave sleep phase, during which the body's largest natural GH pulse occurs. Research shows Ipamorelin administration aligns with improved sleep architecture and amplified nocturnal GH secretion.

Research Applications

Ipamorelin is used in body composition research, anti-aging studies, sleep quality research, skin aging models, and as the GHSR component in combination GH peptide protocols — most commonly paired with CJC-1295 Without DAC or Sermorelin.

*For research use only. Not for human consumption.*